Literature DB >> 20448183

Cross-reacting antibodies enhance dengue virus infection in humans.

Wanwisa Dejnirattisai1, Amonrat Jumnainsong, Naruthai Onsirisakul, Patricia Fitton, Sirijitt Vasanawathana, Wannee Limpitikul, Chunya Puttikhunt, Carolyn Edwards, Thaneeya Duangchinda, Sunpetchuda Supasa, Kriangkrai Chawansuntati, Prida Malasit, Juthathip Mongkolsapaya, Gavin Screaton.   

Abstract

Dengue virus co-circulates as four serotypes, and sequential infections with more than one serotype are common. One hypothesis for the increased severity seen in secondary infections is antibody-dependent enhancement (ADE) leading to increased replication in Fc receptor-bearing cells. In this study, we have generated a panel of human monoclonal antibodies to dengue virus. Antibodies to the structural precursor-membrane protein (prM) form a major component of the response. These antibodies are highly cross-reactive among the dengue virus serotypes and, even at high concentrations, do not neutralize infection but potently promote ADE. We propose that the partial cleavage of prM from the viral surface reduces the density of antigen available for viral neutralization, leaving dengue viruses susceptible to ADE by antibody to prM, a finding that has implications for future vaccine design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448183      PMCID: PMC3837288          DOI: 10.1126/science.1185181

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  20 in total

1.  Novel anti-dengue monoclonal antibody recognizing conformational structure of the prM-E heterodimeric complex of dengue virus.

Authors:  Chunya Puttikhunt; Poonsook Keelapang; Nuanpan Khemnu; Nopporn Sittisombut; Watchara Kasinrerk; Prida Malasit
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

Review 2.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction.

Authors:  Jiraphan Junjhon; Matthawee Lausumpao; Sunpetchuda Supasa; Sansanee Noisakran; Adisak Songjaeng; Prakaimuk Saraithong; Kridsada Chaichoun; Utaiwan Utaipat; Poonsook Keelapang; Amornrat Kanjanahaluethai; Chunya Puttikhunt; Watchara Kasinrerk; Prida Malasit; Nopporn Sittisombut
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

4.  The flavivirus precursor membrane-envelope protein complex: structure and maturation.

Authors:  Long Li; Shee-Mei Lok; I-Mei Yu; Ying Zhang; Richard J Kuhn; Jue Chen; Michael G Rossmann
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

5.  Structure of the immature dengue virus at low pH primes proteolytic maturation.

Authors:  I-Mei Yu; Wei Zhang; Heather A Holdaway; Long Li; Victor A Kostyuchenko; Paul R Chipman; Richard J Kuhn; Michael G Rossmann; Jue Chen
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

6.  The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue.

Authors:  N Jirakanjanakit; T Sanohsomneing; S Yoksan; N Bhamarapravati
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Sep-Oct       Impact factor: 2.184

7.  Production of anti-dengue NS1 monoclonal antibodies by DNA immunization.

Authors:  Chunya Puttikhunt; Watchara Kasinrerk; Supa Srisa-ad; Thaneeya Duangchinda; Waraporn Silakate; Seangdeun Moonsom; Nopporn Sittisombut; Prida Malasit
Journal:  J Virol Methods       Date:  2003-04       Impact factor: 2.014

8.  Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II.

Authors:  Chih-Yun Lai; Wen-Yang Tsai; Su-Ru Lin; Chuan-Liang Kao; Hsien-Ping Hu; Chwan-Chuen King; Han-Chung Wu; Gwong-Jen Chang; Wei-Kung Wang
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

9.  Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.

Authors:  N Sangkawibha; S Rojanasuphot; S Ahandrik; S Viriyapongse; S Jatanasen; V Salitul; B Phanthumachinda; S B Halstead
Journal:  Am J Epidemiol       Date:  1984-11       Impact factor: 4.897

10.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.

Authors:  S B Halstead; E J O'Rourke
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  399 in total

1.  B-cell responses during primary and secondary dengue virus infections in humans.

Authors:  Anuja Mathew; Kim West; Siripen Kalayanarooj; Robert V Gibbons; Anon Srikiatkhachorn; Sharone Green; Daniel Libraty; Smita Jaiswal; Alan L Rothman
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

2.  Positive selection sites in the surface genes of dengue virus: phylogenetic analysis of the interserotypic branches of the four serotypes.

Authors:  Patsarin Rodpothong; Prasert Auewarakul
Journal:  Virus Genes       Date:  2012-01-06       Impact factor: 2.332

Review 3.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

4.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

5.  Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles.

Authors:  Jiraphan Junjhon; Thomas J Edwards; Utaiwan Utaipat; Valorie D Bowman; Heather A Holdaway; Wei Zhang; Poonsook Keelapang; Chunya Puttikhunt; Rushika Perera; Paul R Chipman; Watchara Kasinrerk; Prida Malasit; Richard J Kuhn; Nopporn Sittisombut
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

6.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

7.  The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

Authors:  Iris Valdés; Lázaro Gil; Yaremis Romero; Jorge Castro; Pedro Puente; Laura Lazo; Ernesto Marcos; María G Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

Review 8.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

9.  Altered profile of regulatory T cells and associated cytokines in mild and moderate dengue.

Authors:  H Tillu; A S Tripathy; P V Reshmi; D Cecilia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

10.  Fluorescently labeled dengue viruses as probes to identify antigen-specific memory B cells by multiparametric flow cytometry.

Authors:  Marcia Woda; Anuja Mathew
Journal:  J Immunol Methods       Date:  2014-12-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.